Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following treatment with benralizumab or mepolizumab

被引：0

作者：

Bourdin, Arnaud ^{[1
]}

Wechsler, Michael E. ^{[2
]}

Jackson, David J. ^{[3
]}

Siddiqui, Salman ^{[4
]}

Baudy, Peter ^{[5
]}

Menzies-Gow, Andrew ^{[6
]}

Necander, Sofia ^{[7
]}

Shavit, Anat ^{[6
]}

Walton, Claire ^{[8
]}

机构：

[1] Univ Montpellier, Dept Resp Dis, CHU Montpellier, INSERM, Montpellier, France

[2] Natl Jewish Hlth, Dept Med, Denver, CO USA

[3] Kings Coll London, Guys Severe Asthma Ctr, London, England

[4] Imperial Coll London, Hammersmith & Royal Brompton Hosp, Natl Heart & Lung Inst, London, England

[5] AstraZeneca, Resp & Immunol US Med, Wilmington, DE USA

[6] AstraZeneca, BioPharmaceutials Med, Cambridge, England

[7] AstraZeneca, Late Stage Resp & Immunol, BioPharmaceut R&D, AstraZeneca Med, Gothenburg, Sweden

[8] AstraZeneca, Late Stage Resp & Immunol, BioPharmaceut R&D, Cambridge, England

来源：

EUROPEAN RESPIRATORY JOURNAL | 2024年 / 64卷

关键词：

D O I：

10.1183/13993003.congress-2024.PA5364

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页数：2

共 50 条

[21] Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis
McBrien, C. N.
Menzies-Gow, A.
DRUGS OF TODAY, 2018, 54 (02) : 93 - 101
[22] The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients
Kitamura, Noboru
Hamaguchi, Marina
Nishihara, Masahiro
Ikumi, Natsumi
Sugiyama, Kaita
Nagasawa, Yosuke
Tsuzuki, Hiroshi
Yoshizawa, Shoei
Tanikawa, Yutaka
Oshima, Masashi
Asatani, Shinya
Kobayashi, Hitomi
Takei, Masami
ALLERGOLOGY INTERNATIONAL, 2021, 70 (01) : 148 - 149
[23] Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis
Moiseev, Sergey
Zagvozdkina, Eugenia
Kazarina, Viktoria
Bulanov, Nikolai
Novikov, Pavel
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 144 (02) : 621 - 621
[24] Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?
Akdime, Florie
Puechal, Xavier
Roche, Nicolas
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (07): : 2942 - 2943
[25] Asthma follow-up and treatment in a group of 28 patients with eosinophilic granulomatosis with polyangiitis (EGPA)
Latorre, Manuela
Novelli, Federica
Baldini, Chiara
Bacci, Elena
Seccia, Veronica
Cianchetti, Silvana
Bombardieri, Stefano
Luigi, Pier
EUROPEAN RESPIRATORY JOURNAL, 2013, 42
[26] BENRALIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): RESULTS FROM A EUROPEAN MULTICENTER STUDY ON 121 PATIENTS
Bettiol, A.
Mattioli, I.
Urban, M. L.
Bello, F.
Padoan, R.
Groh, M.
Lopalco, G.
Egan, A.
Cottin, V.
Fraticelli, P.
Crimi, C.
Del Giacco, S.
Schroeder, J.
Moi, L.
Jayne, D.
Vaglio, A.
Emmi, G.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 196 - 197
[27] Induction of Remission Following Treatment with Benralizumab in a 16-Year-Old Male with Eosinophilic Granulomatosis with Polyangiitis
Byrd, M.
Bautista, M. V.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[28] Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis
Matsuno, Osamu
Minamoto, Seijiro
RESPIRATORY MEDICINE CASE REPORTS, 2022, 40
[29] Benralizumab in eosinophilic granulomatosis with polyangiitis
Laorden, Daniel
Romero, David
Dominguez-Ortega, Javier
MEDICINA CLINICA, 2022, 158 (10): : 441 - +
[30] Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission
Cremonezi Lammoglia, B.
de Aguiar Trevise, L.
Paslar Leal, T.
Pereira Lopes Vieira Pinto, M.
Hasselmann, G.
Salles Rosa Neto, N.
REUMATISMO, 2023, 75 (04) : 208 - 214

← 1 2 3 4 5 →